A Phase I/II Open-Label Multicenter Study to Evaluate the Safety and Efficacy of AK-01 as Monotherapy in Patients With Locally Advanced or Metastatic Solid Tumors
Phase of Trial: Phase I/II
Latest Information Update: 30 Apr 2018
At a glance
- Drugs AK 01 (Primary)
- Indications Breast cancer; Small cell lung cancer; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors AurKa Pharma
- 24 Apr 2018 Planned number of patients changed from 90 to 131.
- 17 May 2017 Status changed from not yet recruiting to recruiting.
- 20 Apr 2017 Planned initiation date changed from 20 Apr 2017 to 8 May 2017.